# Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease

> **NCT07509034** · PHASE1 · NOT_YET_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 40 (estimated)

## Conditions studied

- Extensive-Stage Small Cell Lung Cancer
- Extrapulmonary Neuroendocrine Carcinoma
- Recurrent or Refractory
- Solid Tumors

## Interventions

- **DRUG:** Autologous B7-H3 CAR T
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT07509034
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-21
- **Primary completion:** 2030-01-30
- **Final completion:** 2031-01-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07509034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07509034, "Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07509034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*